Cerebral Venous Sinus Thrombosis With Thrombocytopenia After Ad26.COV2.S Vaccination | Coagulation Disorders | JN Learning | AMA Ed Hub [Skip to Content]
[Skip to Content Landing]

US Case Reports of Cerebral Venous Sinus Thrombosis With Thrombocytopenia After Ad26.COV2.S Vaccination, March 2 to April 21, 2021

Educational Objective
To identify the key insights or developments described in this article
Key Points

Question  What were the clinical characteristics of the first US patients reported to have cerebral venous sinus thrombosis (CVST) with thrombocytopenia following receipt of the Ad26.COV2.S (Janssen/Johnson & Johnson) COVID-19 vaccine?

Findings  In this case series of 12 patients, all were women, younger than 60 years, and had symptom onset ranging from 6 to 15 days after vaccination requiring hospitalization. Of 11 patients with heparin-platelet factor 4 enzyme-linked immunosorbent assay (ELISA) heparin-induced thrombocytopenia (HIT) antibody test results, all were positive. At last follow-up, outcomes were death (n = 3), intensive care unit (ICU) care (n = 3), non-ICU hospitalization (n = 2), and discharge to home (n = 4).

Meaning  This case series may inform clinical guidance and investigations into the potential relationship between the Ad26.COV2.S vaccine and CVST with thrombocytopenia.

Abstract

Importance  Cerebral venous sinus thrombosis (CVST) with thrombocytopenia, a rare and serious condition, has been described in Europe following receipt of the ChAdOx1 nCoV-19 vaccine (Oxford/AstraZeneca), which uses a chimpanzee adenoviral vector. A mechanism similar to autoimmune heparin-induced thrombocytopenia (HIT) has been proposed. In the US, the Ad26.COV2.S COVID-19 vaccine (Janssen/Johnson & Johnson), which uses a human adenoviral vector, received Emergency Use Authorization (EUA) on February 27, 2021. By April 12, 2021, approximately 7 million Ad26.COV2.S vaccine doses had been given in the US, and 6 cases of CVST with thrombocytopenia had been identified among the recipients, resulting in a temporary national pause in vaccination with this product on April 13, 2021.

Objective  To describe reports of CVST with thrombocytopenia following Ad26.COV2.S vaccine receipt.

Design, Setting, and Participants  Case series of 12 US patients with CVST and thrombocytopenia following use of Ad26.COV2.S vaccine under EUA reported to the Vaccine Adverse Event Reporting System (VAERS) from March 2 to April 21, 2021 (with follow-up reported through April 21, 2021).

Exposures  Receipt of Ad26.COV2.S vaccine.

Main Outcomes and Measures  Clinical course, imaging, laboratory tests, and outcomes after CVST diagnosis obtained from VAERS reports, medical record review, and discussion with clinicians.

Results  Patients’ ages ranged from 18 to younger than 60 years; all were White women, reported from 11 states. Seven patients had at least 1 CVST risk factor, including obesity (n = 6), hypothyroidism (n = 1), and oral contraceptive use (n = 1); none had documented prior heparin exposure. Time from Ad26.COV2.S vaccination to symptom onset ranged from 6 to 15 days. Eleven patients initially presented with headache; 1 patient initially presented with back pain and later developed headache. Of the 12 patients with CVST, 7 also had intracerebral hemorrhage; 8 had non-CVST thromboses. After diagnosis of CVST, 6 patients initially received heparin treatment. Platelet nadir ranged from 9 ×103/µL to 127 ×103/µL. All 11 patients tested for the heparin-platelet factor 4 HIT antibody by enzyme-linked immunosorbent assay (ELISA) screening had positive results. All patients were hospitalized (10 in an intensive care unit [ICU]). As of April 21, 2021, outcomes were death (n = 3), continued ICU care (n = 3), continued non-ICU hospitalization (n = 2), and discharged home (n = 4).

Conclusions and Relevance  The initial 12 US cases of CVST with thrombocytopenia after Ad26.COV2.S vaccination represent serious events. This case series may inform clinical guidance as Ad26.COV2.S vaccination resumes in the US as well as investigations into the potential relationship between Ad26.COV2.S vaccine and CVST with thrombocytopenia.

Sign in to take quiz and track your certificates

Buy This Activity

JN Learning™ is the home for CME and MOC from the JAMA Network. Search by specialty or US state and earn AMA PRA Category 1 CME Credit™ from articles, audio, Clinical Challenges and more. Learn more about CME/MOC

Article Information

Corresponding Author: Isaac See, MD, Centers for Disease Control and Prevention COVID-19 Response Team, 1600 Clifton Rd, HT 16-3, Atlanta, GA 30329 (isee@cdc.gov).

Accepted for Publication: April 26, 2021.

Published Online: April 30, 2021. doi:10.1001/jama.2021.7517

Author Contributions: Drs Lale and See had full access to all of the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis.

Concept and design: See, Lale, Guh, Shimabukuro, Wheeler, Edwards, Creech, Clark, DeStefano, Broder.

Acquisition, analysis, or interpretation of data: See, Su, Lale, Woo, Guh, Shimabukuro, Streiff, Rao, Wheeler, Beavers, Durbin, Miller, Mba-Jonas, Nair, Nguyen, Talaat, Urrutia, Creech, Clark, Broder.

Drafting of the manuscript: See, Lale, Woo, Guh, Rao, Nguyen, Broder.

Critical revision of the manuscript for important intellectual content: See, Su, Guh, Shimabukuro, Streiff, Wheeler, Beavers, Durbin, Edwards, Miller, Mba-Jonas, Nair, Talaat, Urrutia, Creech, Clark, DeStefano, Broder.

Statistical analysis: See, Su, Lale, Guh.

Administrative, technical, or material support: Su, Lale, Guh, Shimabukuro, Streiff, Rao, Wheeler, Miller, Nair, Nguyen, Talaat, Creech, Clark, Broder.

Supervision: See, Shimabukuro, Edwards, Nair, Clark, DeStefano, Broder.

Other - neurological expertise: Urrutia.

Other - clinical expertise: Wheeler.

Other - reading all serious reports: Woo.

Conflict of Interest Disclosures: Dr Streiff reported receiving grants from Janssen for the Cassini clinical trial of rivaroxaban for prevention of cancer-associated thrombosis; personal fees from Janssen for serving on the advisory board for the Cassini trial; from Bayer, Bristol Myers Squibb, and Dispersol for providing consultative advice; from Bayer for CME lectures; and from Pfizer for CME lectures and serving on the advisory board. Dr Strieff also reported receiving grants from NHLBI for a study on missed doses in VTE prophylaxis, from AHRQ for work on individualized feedback on VTE prophylaxis practices, and from PCORI for research on patient education to improve acceptance of VTE prophylaxis. Dr Durbin reported receiving grants from Pfizer as an investigator for the Pfizer COVID-19 vaccine trial and grants from NIH for serving as the site principal investigator for the AstraZeneca COVID-19 vaccine trial; receiving personal fees from Merck for consultative advice on dengue vaccine development; and serving on the scientific advisory board for Valneva. Dr Edwards reported receiving grants from NIH and providing consultative advice to BioNet and IBM; she also reported serving on data and safety monitoring boards of Pfizer, Moderna, Merck, Sanofi, Roche, X-4 Pharma, and Seqirus. Dr Talaat reported receiving grants from Pfizer for serving as the site principal investigator for the phase 3 adult COVID-19 vaccine study and the phase 1-3 pediatric (under 12) COVID-19 vaccine study, both at Johns Hopkins University; she also reported receiving grants from the NIH-Coronavirus Prevention Network for serving as a co-investigator on the phase 3 AstraZeneca COVID-19 vaccine trial in adults. Dr Urratia reported receiving grants from Genentech Inc for serving as the site principal investigator on the TIMELESS trial and his work on the investigator-sponsored OPTIMIST main trial. Dr Creech reported receiving grants from Merck as well as personal fees from Altimmune, Horizon, Karius, Premier, and Astellas for providing consultative advice. No other disclosures were reported.

Funding/Support: This work was supported by the Centers for Disease Control and Prevention (CDC) Clinical Immunization Safety Assessment (CISA) Project contracts 200-2012-53664 to Johns Hopkins University and 200-2012-50430 to Vanderbilt University Medical Center.

Role of the Funder/Sponsor: CDC provided funding to Drs Creech, Durbin, Edwards, Streiff, Talaat, Urrutia, Walker, and Wheeler. CDC, including CDC authors along with non-CDC coauthors, conducted the investigations; performed collection, management, analysis, and interpretation of the data; was involved in preparation, review, and approval of the manuscript; and made the decision to submit the manuscript for publication.

Disclaimer: The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the CDC or the Food and Drug Administration (FDA). Mention of a product or company name is for identification purposes only and does not constitute endorsement by the CDC and FDA.

Additional Contributions: We thank the following CDC staff who contributed to this article without compensation aside from their salaries. For data collection: Kathy Byrd, MD, MPH (CDC COVID-19 Response), Margaret Cortese, MD (CDC COVID-19 Response), Amelia Jazwa, MSPH (CDC COVID-19 Response), Anamika Khatri-Dua, MD (CDC COVID-19 Response), Susan Lukacs, DO, MSPH (CDC COVID-19 Response), Mike McNeil, MD, MPH (CDC COVID-19 Response), Monica Parise, MD (CDC COVID-19 Response), Allan Taylor, MD, MPH (CDC COVID-19 Response). For leadership and support: Denise Cardo, MD (CDC COVID-19 Response). We also thank the following individuals who contributed to this article with funding support through the CISA Project. For programmatic support: Paula Campbell, MS, MPH (Vanderbilt University) and Braxton Hern, BS (Vanderbilt University). For vaccine safety expertise: Elizabeth Barnett, MD (Boston University), Neal Halsey, MD (Johns Hopkins University), Thomas Kickler, MD (Johns Hopkins University), Nicola Klein, MD, PhD (Kaiser Permanente Northern California), Philip LaRussa, MD (Columbia University), Stephen Pelton, MD (Boston University), Elizabeth Schlaudecker, MD, MPH (Cincinnati Children’s Hospital Medical Center), Michael Smith, MD, MSCE (Duke University), Mary Staat, MD, MPH (Cincinnati Children’s Hospital Medical Center), Melissa Stockwell (Columbia University), Emmanuel “Chip” Walter, MD, MPH (Duke University), and Jennifer Yui, MD, MS (Johns Hopkins University). We also thank the clinical staff who have cared for these patients and who reported these events to VAERS..

References
1.
US Food and Drug Administration. Janssen COVID-19 vaccine. Accessed April 17, 2021. https://www.fda.gov/emergency-preparedness-and-response/coronavirus-disease-2019-covid-19/janssen-covid-19-vaccine
2.
CDC Health Alert Network. Cases of cerebral venous sinus thrombosis with thrombocytopenia after receipt of the Johnson & Johnson COVID-19 vaccine. Accessed April 17, 2021. https://emergency.cdc.gov/han/2021/han00442.asp
3.
Centers for Disease Control and Prevention. COVID Data Tracker: COVID-19 vaccinations in the United States. Accessed April 17, 2021. https://covid.cdc.gov/covid-data-tracker/#vaccinations
4.
European Medicines Agency. COVID-19 Vaccine AstraZeneca: benefits still outweigh the risks despite possible link to rare blood clots with low blood platelets. Accessed April 20, 2021. https://www.ema.europa.eu/en/news/covid-19-vaccine-astrazeneca-benefits-still-outweigh-risks-despite-possible-link-rare-blood-clots
5.
World Health Organization. Global Advisory Committee on Vaccine Safety (GACVS) review of latest evidence of rare adverse blood coagulation events with AstraZeneca COVID-19 Vaccine (Vaxzevria and Covishield). Accessed April 24, 2021. https://www.who.int/news/item/16-04-2021-global-advisory-committee-on-vaccine-safety-(gacvs)-review-of-latest-evidence-of-rare-adverse-blood-coagulation-events-with-astrazeneca-covid-19-vaccine-(vaxzevria-and-covishield)
6.
Ramasamy  MN , Minassian  AM , Ewer  KJ ,  et al; Oxford COVID Vaccine Trial Group.  Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial.   Lancet. 2021;396(10267):1979-1993. doi:10.1016/S0140-6736(20)32466-1 PubMedGoogle ScholarCrossref
7.
Idiculla  PS , Gurala  D , Palanisamy  M , Vijayakumar  R , Dhandapani  S , Nagarajan  E .  Cerebral Venous Thrombosis: A Comprehensive Review.   Eur Neurol. 2020;83(4):369-379. doi:10.1159/000509802 PubMedGoogle ScholarCrossref
8.
Warkentin  TE , Basciano  PA , Knopman  J , Bernstein  RA .  Spontaneous heparin-induced thrombocytopenia syndrome: 2 new cases and a proposal for defining this disorder.   Blood. 2014;123(23):3651-3654. doi:10.1182/blood-2014-01-549741 PubMedGoogle ScholarCrossref
9.
Greinacher  A , Thiele  T , Warkentin  TE , Weisser  K , Kyrle  PA , Eichinger  S .  Thrombotic thrombocytopenia after ChAdOx1 nCov-19 vaccination.   N Engl J Med. Published online April 9, 2021. doi:10.1056/NEJMoa2104840 PubMedGoogle Scholar
10.
Schultz  NH , Sørvoll  IH , Michelsen  AE ,  et al.  Thrombosis and thrombocytopenia after ChAdOx1 nCoV-19 vaccination.   N Engl J Med. Published online April 9, 2021. doi:10.1056/NEJMoa2104882 PubMedGoogle Scholar
11.
Scully  M , Singh  D , Lown  R ,  et al.  Pathologic antibodies to platelet factor 4 after ChAdOx1 nCov-19 vaccination.   N Engl J Med. Published online April 16, 2021. doi:10.1056/NEJMoa2105385 PubMedGoogle Scholar
12.
Food and Drug Administration. FDA Briefing Document: Janssen Ad26.COV2.S Vaccine for the Prevention of COVID-19. Vaccines and Related Biological Products Advisory Committee Meeting. February 26, 2021. Accessed April 27, 2021. https://www.fda.gov/media/146217/download
13.
Muir  KL , Kallam  A , Koepsell  SA , Gundabolu  K .  Thrombotic thrombocytopenia after Ad26.COV2.S vaccination.   N Engl J Med. Published online April 14, 2021. doi:10.1056/NEJMc2105869 PubMedGoogle Scholar
14.
Joint CDC and FDA statement on Johnson & Johnson COVID-19 vaccine. April 13, 2021. Accessed April 19, 2021. https://www.cdc.gov/media/releases/2021/s0413-JJ-vaccine.html
15.
Shay  DK , Gee  J , Su  JR ,  et al.  Safety monitoring of the Janssen (Johnson & Johnson) COVID-19 vaccine—United States, March–April 2021.   MMWR Morb Mortal Wkly Rep. Published online April 30, 2021. doi:10.15585/mmwr.mm7018e2Google Scholar
16.
MacNeil  JR , Su  JR , Broder  KR ,  et al  Updated recommendations from the Advisory Committee on Immunization Practices for use of the Janssen (Johnson & Johnson) COVID-19 vaccine after reports of thrombosis with thrombocytopenia syndrome among vaccine recipients—United States, April 2021.   MMWR Morb Mortal Wkly Rep. Published online April 27, 2021. doi:10.15585/mmwr.mm7017e4Google Scholar
17.
Centers for Disease Control and Prevention. Clinical Immunization Safety Assessment (CISA) Project. Accessed April 24, 2021. https://www.cdc.gov/vaccinesafety/ensuringsafety/monitoring/cisa/index.html
18.
Brighton Collaboration. Interim case definition of thrombosis with thrombocytopenia syndrome. Accessed April 25, 2021. https://brightoncollaboration.us/thrombosis-with-thrombocytopenia-syndrome-interim-case-definition/
19.
Romano  SD , Blackstock  AJ , Taylor  EV ,  et al.  Trends in racial and ethnic disparities in COVID-19 hospitalizations, by region—United States, March-December 2020.   MMWR Morb Mortal Wkly Rep. 2021;70(15):560-565. doi:10.15585/mmwr.mm7015e2 PubMedGoogle ScholarCrossref
20.
Sahu  KK , Jindal  V , Anderson  J , Siddiqui  AD , Jaiyesimi  IA .  Current perspectives on diagnostic assays and anti-PF4 antibodies for the diagnosis of heparin-induced thrombocytopenia.   J Blood Med. 2020;11:267-277. doi:10.2147/JBM.S232648 PubMedGoogle ScholarCrossref
21.
Minet  V , Dogné  J-M , Mullier  F .  Functional assays in the diagnosis of heparin-induced thrombocytopenia: a review.   Molecules. 2017;22(4):617. doi:10.3390/molecules22040617 PubMedGoogle ScholarCrossref
22.
Onwuemene  O , Arepally  GM .  Heparin-induced thrombocytopenia: research and clinical updates.   Hematology Am Soc Hematol Educ Program. 2016;2016(1):262-268. doi:10.1182/asheducation-2016.1.262 PubMedGoogle ScholarCrossref
23.
Food and Drug Administration. Fact sheet for healthcare providers administering vaccine (vaccination providers). The Emergency Use Authorization (EUA) of the Janssen COVID-19 vaccine to prevent coronavirus disease 2019 (COVID-19). Accessed April 24, 2021. https://www.fda.gov/media/146304/download
24.
Greinacher  A , Selleng  K , Warkentin  TE .  Autoimmune heparin-induced thrombocytopenia.   J Thromb Haemost. 2017;15(11):2099-2114. Published online September 28, 2017. doi:10.1111/jth.13813 PubMedGoogle ScholarCrossref
25.
Sadoff  J , Davis  K , Douoguih  M .  Thrombotic thrombocytopenia after Ad26.COV2.S vaccination: response from the manufacturer.   N Engl J Med. Published online April 16, 2021. doi:10.1056/NEJMc2106075 PubMedGoogle Scholar
26.
Nwajei  F , Anand  P , Abdalkader  M ,  et al.  Cerebral venous sinus thromboses in patients with SARS-CoV-2 infection: three cases and a review of the literature.   J Stroke Cerebrovasc Dis. 2020;29(12):105412. doi:10.1016/j.jstrokecerebrovasdis.2020.105412 PubMedGoogle Scholar
27.
CDC. Interim clinical considerations for use of COVID-19 vaccines currently authorized in the United States. Updated April 27, 2021. Accessed April 28, 2021. https://www.cdc.gov/vaccines/covid-19/info-by-product/clinical-considerations.html
28.
American Society of Hematology. Vaccine-induced immune thrombotic thrombocytopenia: frequently asked questions. Accessed April 17, 2021. https://www.hematology.org/covid-19/vaccine-induced-immune-thrombotic-thrombocytopenia
29.
Saposnik  G , Barinagarrementeria  F , Brown  RD  Jr ,  et al; American Heart Association Stroke Council and the Council on Epidemiology and Prevention.  Diagnosis and management of cerebral venous thrombosis: a statement for healthcare professionals from the American Heart Association/American Stroke Association.   Stroke. 2011;42(4):1158-1192. doi:10.1161/STR.0b013e31820a8364 PubMedGoogle ScholarCrossref
30.
American Heart Association. CVST and blood clots potentially related to the J&J COVID-19 vaccine: know the symptoms. Accessed April 25, 2021. https://newsroom.heart.org/news/cvst-and-blood-clots-potentially-related-to-the-j-j-covid-19-vaccine-know-the-symptoms
31.
de Bruijn  SFTM , de Haan  RJ , Stam  J ; Cerebral Venous Sinus Thrombosis Study Group.  Clinical features and prognostic factors of cerebral venous sinus thrombosis in a prospective series of 59 patients.   J Neurol Neurosurg Psychiatry. 2001;70(1):105-108. doi:10.1136/jnnp.70.1.105 PubMedGoogle ScholarCrossref
If you are not a JN Learning subscriber, you can either:
Subscribe to JN Learning for one year
Buy this activity
jn-learning_Modal_Multimedia_LoginSubscribe_Purchase
Close
If you are not a JN Learning subscriber, you can either:
Subscribe to JN Learning for one year
Buy this activity
jn-learning_Modal_Multimedia_LoginSubscribe_Purchase
Close
With a personal account, you can:
  • Access free activities and track your credits
  • Personalize content alerts
  • Customize your interests
  • Fully personalize your learning experience
Education Center Collection Sign In Modal Right
Close

Name Your Search

Save Search
Close
With a personal account, you can:
  • Track your credits
  • Personalize content alerts
  • Customize your interests
  • Fully personalize your learning experience
jn-learning_Modal_SaveSearch_NoAccess_Purchase
Close

Lookup An Activity

or

Close

My Saved Searches

You currently have no searches saved.

Close
With a personal account, you can:
  • Access free activities and track your credits
  • Personalize content alerts
  • Customize your interests
  • Fully personalize your learning experience
Education Center Collection Sign In Modal Right
Close